Nachrichten zur Viatris Inc. Aktie

Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments

We recently published a list of 8 Stocks Under $20 To Invest In Now. In this article, we are going…

Aktienmarkt: Kurs der Viatris-Aktie im Minus (10,0972 €)

An der US-amerikanischen Börse notiert das Wertpapier von Viatris zur Stunde leichter. Der jüngste Kurs betrug 11,20 US-Dollar. An der…

US Biosimilar Market Research 2024-2028 Featuring Leading Players - Pfizer, Novartis, Amgen, Samsung Biologics, Celltrion, and Viatris

Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "US Biosimilar Market: Insights & Forecast (2024-2028)" report has been…

Viatris Inc. (VTRS) Q2 2024 Earnings Call Transcript

…

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.…

Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

…

Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)

…

Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%

The Global Topical Wound Agents Market Size was valued at USD 1.9 Billion in 2023 and the Global Topical Wound…

Viatris Inc. (VTRS) BofA Securities 2024 Health Care Conference (Transcript)

…

Analyst Report: Viatris Inc

…

Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript

…

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

…

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

…

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent By Reuters

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent…

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company…

Viatris Stock Is Still Worth Buying

…

Global Pregabalin Market Size To Worth USD 2.18 Billion By 2033 | CAGR of 2.82%

The Global Pregabalin Market Size was Valued at USD 1.65 Billion in 2023 and the Worldwide Pregabalin Market Size is…

Viatris Inc. (VTRS) R&D Event (Transcript)

…

Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript

…

Viatris reports upbeat 2024 revenue outlook By Investing.com

Viatris reports upbeat 2024 revenue outlook…

Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Regeneron Gains After Eye-Drug Patent Victory Over Viatris

Regeneron Pharmaceuticals Inc. rose the most since August after a court ruled that the drugmaker’s patent rights were infringed by…

Regeneron surges after patent case ruling against Viatris By Investing.com

Regeneron surges after patent case ruling against Viatris…

Kurs der Viatris-Aktie verharrt auf Vortags-Niveau (8,32081 €)

CODE Das Papier notiert zur Stunde bei 9,14 US-Dollar. Kaum auffällig ist derzeit am Aktienmarkt der Kurs von Viatris. Das…

Viatris-Aktie: Kurs fällt ab (8,50908 €)

Im US-amerikanischen Wertpapierhandel liegt der Anteilsschein von Viatris zur Stunde im Minus. Der jüngste Kurs betrug 9,32 US-Dollar. Am Aktienmarkt…

Analyst Report: Viatris Inc

…

Viatris Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Viatris Inc. (VTRS) Q3 2023 Earnings Conference Call Transcript

…

Viatris-Aktie leicht im Minus (8,91294 €)

An der US-amerikanischen Börse liegt die Viatris-Aktie derzeit im Minus. Zuletzt zahlten Investoren für die Aktie 9,37 US-Dollar. Am US-amerikanischen…

: Viatris and Ocuphire Pharma get FDA green light for eye treatment

Viatris Inc. VTRS and Ocuphire Pharma Inc. OCUP said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi…

Specialty Generics Market to Reach USD 184.8 Billion by 2032; Increasing Capacity for Walking & Physical Activities to Propel Growth, says The Brainy Insights

Global specialty generics market size from USD 70.0 billion in 2022 to USD 184.8 billion, growing at a CAGR of…

dpa-AFX ProFeed